Get the Stockscreener App
21.19
2.12%
0.44
Innoviva Inc stock is traded at $21.19, with a volume of 448.81K.
It is up +2.12% in the last 24 hours and down -2.53% over the past month.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
See More
Previous Close:
$20.75
Open:
$20.72
24h Volume:
448.81K
Relative Volume:
0.53
Market Cap:
$1.53B
Revenue:
$434.49M
Net Income/Loss:
$504.34M
P/E Ratio:
3.5236
EPS:
6.0138
Net Cash Flow:
$181.97M
1W Performance:
+3.32%
1M Performance:
-2.53%
6M Performance:
-6.65%
1Y Performance:
+1.48%
1-Day Range:
$20.68
$21.21
1-Week Range:
$20.39
$21.21
52-Week Range:
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
21.19 | 1.50B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | BTIG Research | Buy |
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva, Inc. (INVA) Stock Forecasts - Yahoo! Finance Canada
HC Wainwright Issues Positive Forecast for Innoviva Earnings - MarketBeat
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com India
Three Innoviva therapies named finalists for Prix Galien award - Investing.com
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award - Yahoo Finance
How (INVA) Movements Inform Risk Allocation Models - Stock Traders Daily
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA? - webull.com
Innoviva stock price target reiterated at $46 by H.C. Wainwright - Investing.com Nigeria
Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Innoviva Stock Price Forecast. Should You Buy INVA? - StockInvest.us
Innoviva Inc (INVA) Stock News Today - tradingkey.com
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors - Yahoo Finance
Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Innoviva (INVA) Stock Can Revenue Growth Offset A Sharp Profit Reversal - webull.com
Cantor Fitzgerald Lowers Innoviva (NASDAQ:INVA) Price Target to $34.00 - MarketBeat
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic (NASDAQ:INVA) - Seeking Alpha
BTIG Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Innoviva shifts from royalties to healthcare pr... - Pluang
Innoviva (NASDAQ:INVA) Announces Quarterly Earnings Results, Misses Expectations By $1.58 EPS - MarketBeat
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress - BioSpace
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Innoviva: Q2 Earnings Snapshot - Barchart.com
Innoviva, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Innoviva, Inc. Q2 2026: Revenue $119.6M, EPS $(1.14) — 10-Q Summary - TradingView
Innoviva reports Q2 2026 revenue $119.6M, net loss $83.4M on investment markdowns - TradingView
Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, vs. FactSet Est of $111.0M - marketscreener.com
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 5, 2025. - marketscreener.com
BRIEF-Innoviva Q2 Royalty Revenue USD 56.334 Million - TradingView
Innoviva, Inc. (INVA) Stock Analysis: Biotech Powerhouse With 70% Upside Potential - directorstalkinterviews.com
Innoviva Inc. (INVA) Pulls Back 0.95% to $20.77 as Traders Eye Key Support ZoneSwing Entry Signals - dars.gov.et
Empowered Funds LLC Purchases 93,424 Shares of Innoviva, Inc. $INVA - MarketBeat
First Trust Advisors LP Grows Stock Holdings in Innoviva, Inc. $INVA - MarketBeat
Innoviva, Inc. $INVA Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Innoviva, Inc. Revenue Breakdown – NASDAQ:INVA - TradingView
THRX5561968 Bond Coupon Profile — Rate & Payments - TradingView
Vanguard Capital Management (INVA) reports 3.7M Innoviva shares in Schedule 13G - Stock Titan
Innoviva (INVA) Projected to Release Earnings on Wednesday - MarketBeat
Innoviva earnings up next: Can LYNX platform pivot pay off? By Investing.com - Investing.com Nigeria
Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation - ChartMill
Innoviva Inc (INVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
INVA|Innoviva Inc|Price:20.970|Chg%:-0.250 - TradingKey
Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Innoviva Inc (INVA) Earnings Date & Reports & Earnings News - tradingkey.com
Thai FDA approves Dr Reddy’s gonorrhoea antibiotic - ET Pharma
Innoviva Inc (INVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Innoviva Market Sentiment - Benzinga España
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Innoviva Inc (INVA) Balance Sheet - TradingKey
Innoviva, Inc. Revenue Breakdown – MUN:HVE - TradingView
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):